Imatinib mesylate for the treatment of pulmonary arterial hypertension

Bibliography

• Badesch DB, Champion HC, Sanchez MA, Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl S):55-66
   Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619
   PubMed Web of Science ®Google Scholar
• Galie N, Hoeper MM, Humbert M, Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537
   PubMed Web of Science ®Google Scholar
• Rosenkranz S. Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol 2007;96:527-41
   PubMed Web of Science ®Google Scholar
• Simonneau G, Robbins IM, Beghetti M, Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(Suppl S):S43-54
   PubMedGoogle Scholar
• Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65
   PubMed Web of Science ®Google Scholar
• Van Wolferen SA, Marcus JT, Boonstra A, Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007;28:1250-7
   PubMed Web of Science ®Google Scholar
• Haworth SG. The cell and molecular biology of right ventricular dysfunction in pulmonary hypertension. Eur Heart J 2007;28(Suppl H):H10-16
   Google Scholar
• D'Alonzo GE, Barst RJ, Ayres SM, Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991;115:343-9
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Gomberg-Maitland M, Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164-72
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-63
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Dony E, Ghofrani HA, Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21
   PubMed Web of Science ®Google Scholar
• Perros F, Montani D, Dorfmuller P, Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:81-8
   PubMed Web of Science ®Google Scholar
• Hassoun PM, Mouthon L, Barbera JA, Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54(Suppl S):S10-19
   PubMedGoogle Scholar
• Morrell NW, Adnot S, Archer SL, Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl S):S20-31
   PubMedGoogle Scholar
• Galie N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010;31:2080-6
   PubMed Web of Science ®Google Scholar
• Newman JH, Trembath RC, Morse JA, Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 2004;43(Suppl S):33S-39S
   PubMedGoogle Scholar
• Machado R, Eickelberg O, Elliott CG, Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl S):S32-42
   PubMedGoogle Scholar
• Tuder RM, Abman SH, Braun T, Development and pathology of pulmonary hypertension. J Am Coll Cardiol 2009;54(Suppl S):S3-9
   PubMedGoogle Scholar
• Stenmark KR, Gerasimovskaya E, Nemenoff RA, Das M. Hypoxic activation of adventitial fibroblasts: role in vascular remodeling. Chest 2002;122(Suppl 6):326S-334S
   PubMed Web of Science ®Google Scholar
• Tuder RM, Voelkel N. Pulmonary hypertension and inflammation. J Lab Clin Med 2010;132:16-24
   Web of Science ®Google Scholar
• Barst RJ, Gibbs SR, Ghofrani HA, Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl S):S78-84
   PubMedGoogle Scholar
• Badesch DB, Abman SH, Simonneau G, Medical therapy for pulmonary arterial hypertension. Updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-28
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jais X, Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302
   PubMed Web of Science ®Google Scholar
• Galie N, Brundage BH, Ghofrani HA, Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-903
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A, Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galié N, Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9
   PubMed Web of Science ®Google Scholar
• Oudiz RJ, Galie N, Olschewski H, Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:1971-81
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N, Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4
   PubMed Web of Science ®Google Scholar
• Humbert M, Segal ES, Kiely DG, Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-40
   PubMed Web of Science ®Google Scholar
• Simmoneau G, Rubin LJ, Galie N, Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-30
   PubMed Web of Science ®Google Scholar
• Chockalingam A, Gnanavelu G, Venkatesan S, Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol 2005;99:91-5
   PubMed Web of Science ®Google Scholar
• Galie N, Manes A, Negro L, A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403
   PubMed Web of Science ®Google Scholar
• Chen SJ, Chen YF, Meng QC, Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79:2122-31
   PubMed Web of Science ®Google Scholar
• Falcetti E, Hall SM, Phillips PG, Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182:1161-70
   PubMed Web of Science ®Google Scholar
• Wharton J, Davie N, Upton PD, Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000;102:3130-6
   PubMed Web of Science ®Google Scholar
• Wharton J, Strange JW, Möller GM, Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005;172:105-13
   PubMed Web of Science ®Google Scholar
• Haga M, Yamashita A, Paszkowiak J, Oscillatory shear stress increases smooth muscle cell proliferation and Akt phosphorylation. J Vasc Surg 2003;37:1277-84
   PubMed Web of Science ®Google Scholar
• Sterpetti AV, Cucina A, Santoro L, Modulation of arterial smooth muscle cell growth by haemodynamic forces. Eur J Vasc Surg 1992;6:16-20
   PubMedGoogle Scholar
• Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev 2004;15:237-54
   PubMed Web of Science ®Google Scholar
• Grimminger F, Schermuly RT. PDGF receptor and its antagonists: role in treatment of PAH. Adv Exp Med Biol 2010;661:435-46
   PubMed Web of Science ®Google Scholar
• Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-316
   PubMed Web of Science ®Google Scholar
• Kazlauskas A. Receptor tyrosine kinases and their targets. Curr Opin Genet Dev 1994;4:5-14
   PubMed Web of Science ®Google Scholar
• Rosenkranz S, Kazlauskas A. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors 1999;16:201-16
   PubMed Web of Science ®Google Scholar
• Schwartz SM. Perspectives series: cell adhesion in vascular biology: smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 1997;99:2814-16
   PubMed Web of Science ®Google Scholar
• Ten Freyhaus H, Huntgeburth M, Wingler K, Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res 2006;71:331-41
   PubMed Web of Science ®Google Scholar
• Tanizawa S, Ueda M, van der Loos CM, Expression of platelet derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study. Heart 1996;75:549-56
   PubMed Web of Science ®Google Scholar
• Abe J, Deguchi J, Takuwa Y, Tyrosine phosphorylation of platelet derived growth factor beta receptors in coronary artery lesions: implications for vascular remodelling after directional coronary atherectomy and unstable angina pectoris. Heart 1998;79:400-6
   PubMed Web of Science ®Google Scholar
• Levitzki A. PDGF receptor kinase inhibitors for the treatment of restenosis. Cardiovasc Res 2005;65:581-6
   PubMed Web of Science ®Google Scholar
• Caglayan E, Vantler M, Leppanen O, Disruption of PDGF-dependent PI 3-kinase and PLCgamma activity abolishes vascular smooth muscle cell proliferation and migration and attenuates neointima formation in vivo. J Am Coll Cardiol 2011;57:2527-38
   PubMed Web of Science ®Google Scholar
• Arcot SS, Lipke DW, Gillespie MN, Olson JW. Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem Pharmacol 1993;46:1086-91
   PubMed Web of Science ®Google Scholar
• Cai Y, Han M, Luo L, Increased expression of pdgf and c-myc genes in lungs and pulmonary arteries of pulmonary hypertensive rats induced by hypoxia. Chin Med Sci J 1996;11:152-6
   PubMedGoogle Scholar
• Huang Q, Sun R. Changes of PDGF-alpha and beta receptor gene expression in hypoxic rat pulmonary vessels. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1997;19:470-3
   PubMedGoogle Scholar
• Katayose D, Ohe M, Yamauchi K, Increased expression of PDGF-alpha and beta-chain genes in rat lungs with hypoxic pulmonary hypertension. Am J Physiol 1993;264:L100-6
   PubMed Web of Science ®Google Scholar
• Kwapiszewska G, Wilhelm J, Wolff S, Expression profiling of laser-microdissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension. Respir Res 2005;6:109
   PubMedGoogle Scholar
• Jones R, Capen D, Jacobson M, Munn L. PDGF and microvessel wall remodeling in adult rat lung: imaging PDGF-aa and PDGF-ralpha molecules in progenitor smooth muscle cells developing in experimental pulmonary hypertension. Cell Tissue Res 2006;326:759-69
   PubMed Web of Science ®Google Scholar
• Humbert M, Monti G, Fartoukh M, Platelet-derived growth factor expression in primary pulmonary hypertension: Comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998;11:554-9
   PubMed Web of Science ®Google Scholar
• Lanner MC, Raper M, Pratt WM, Heterotrimeric G proteins and the platelet-derived growth factor receptor-beta contribute to hypoxic proliferation of smooth muscle cells. Am J Respir Cell Mol Biol 2005;33:412-19
   PubMed Web of Science ®Google Scholar
• Balasubramaniam V, Le Cras TD, Ivy DD, Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 2003;284:L826-33
   PubMed Web of Science ®Google Scholar
• Bergsten E, Uutela M, Li X, PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 2001;3:512-16
   PubMed Web of Science ®Google Scholar
• Gilbertson DG, Duff ME, West JW, Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem 2001;276:27406-14
   PubMed Web of Science ®Google Scholar
• LaRochelle WJ, Jeffers M, McDonald WF, PDGF-D, a new protease-activated growth factor. Nat Cell Biol 2001;3:517-21
   PubMed Web of Science ®Google Scholar
• Li X, Ponten A, Aase K, PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2000;2:302-9
   PubMed Web of Science ®Google Scholar
• Leveen P, Pekny M, Gebre-Medhin S, Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 1994;8:1875-87
   PubMed Web of Science ®Google Scholar
• Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242-5
   PubMed Web of Science ®Google Scholar
• Mellgren AM, Smith CL, Olsen GS, Platelet-derived growth factor receptor beta signaling is required for efficient epicardial cell migration and development of two distinct coronary vascular smooth muscle cell populations. Circ Res 2008;103:1393-401
   PubMed Web of Science ®Google Scholar
• Soriano P. Abnormal kidney development and haematological disorders in PDGF beta-receptor mutant mice. Genes Dev 1994;8:1888-96
   PubMed Web of Science ®Google Scholar
• Tallquist MD, Klinghoffer RA, Heuchel R, Retention of PDGFR-beta function in mice in the absence of phosphatidylinositol 3´-kinase and phospholipase Cgamma signalling pathways. Genes Dev 2000;14:3179-90
   PubMed Web of Science ®Google Scholar
• Tallquist MD, Soriano P, Klinghoffer RA. Growth factor signaling pathways in vascular development. Oncogene 1999;18:7917-32
   PubMed Web of Science ®Google Scholar
• Baumer AT, Ten Freyhaus H, Sauer H, PI3 kinase-dependent membrane recruitment of rac-1 and p47phox is critical for alpha PDGF receptor-induced production of reactive oxygen species. J Biol Chem 2008;283:7864-76
   PubMed Web of Science ®Google Scholar
• Chung J, Grammer TC, Lemon KP, PDGF- and insulin-dependent pp70S6K activation mediated by phosphatidylinositol-3-OH-kinase. Nature 1994;370:71-5
   PubMed Web of Science ®Google Scholar
• DeMali KA, Whiteford CC, Ulug ET, Kazlauskas A. Platelet-derived growth factor-dependent cellular transformation requires either phospholipase Cgamma or phosphatidylinositol 3 kinase. J Biol Chem 1997;272:9011-18
   PubMed Web of Science ®Google Scholar
• Fambrough D, McClure K, Kazlauskas A, Lander ES. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes. Cell 1999;97:727-41
   PubMed Web of Science ®Google Scholar
• Joly M, Kazlauskas A, Fay FS, Corvera S. Disruption of PDGF receptor trafficking by mutation of its PI-3 kinase sites. Science 1994;263:684-7
   PubMed Web of Science ®Google Scholar
• Klinghoffer RA, Duckworth B, Valius M, Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity. Mol Cell Biol 1996;16:5905-14
   PubMed Web of Science ®Google Scholar
• Kundra V, Escobedo JA, Kazlauskas A, Regulation of chemotaxis by the platelet-derived growth factor receptor beta. Nature 1994;367:474-6
   PubMed Web of Science ®Google Scholar
• Montmayeur JP, Valius M, Vandenheede J, Kazlauskas A. The platelet-derived growth factor beta-receptor triggers multiple cytoplasmic signaling cascades that arrive at the nucleus at distinguishable inputs. J Biol Chem 1997;272:32670-8
   PubMed Web of Science ®Google Scholar
• Rosenkranz S, DeMali KA, Gelderloos JA, Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis. J Biol Chem 1999;274:28335-43
   PubMed Web of Science ®Google Scholar
• Valius M, Kazlauskas A. Phospholipase C-gamma1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal. Cell 1993;73:321-34
   PubMed Web of Science ®Google Scholar
• Valius M, Secrist J-P, Kazlauskas A. The GTPase activating protein of Ras suppresses platelet-derived growth factor beta receptor signaling by silencing phospholipase C-gamma1. Mol Cell Biol 1995;15:3058-71
   PubMed Web of Science ®Google Scholar
• Ten Freyhaus H, Dagnell M, Leuchs M, Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases. Am J Respir Crit Care Med 2011;183:1092-102
   PubMed Web of Science ®Google Scholar
• Miyake S, Mullane-Robinson KP, Lill NL, Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation. A critical role for Cbl tyrosine kinase-binding domain. J Biol Chem 1999;274:16619-28
   PubMed Web of Science ®Google Scholar
• Rosenkranz S, Ikuno Y, Leong FL, Src family kinases negatively regulate platelet-derived growth factor alpha receptor-dependent signaling and disease progression. J Biol Chem 2000;275:9620-7
   PubMed Web of Science ®Google Scholar
• Kappert K, Paulsson J, Sparwel J, Dynamic changes in the expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation. FASEB J 2007;21:523-34
   PubMed Web of Science ®Google Scholar
• Kappert K, Peters KG, Bohmer FD, Ostman A. Tyrosine phosphatases in vessel wall signaling. Cardiovasc Res 2005;65:587-98
   PubMed Web of Science ®Google Scholar
• Humar R, Kiefer FN, Berns H, Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002;16:771-80
   PubMed Web of Science ®Google Scholar
• Schultz K, Fanburg BL, Beasley D, Hypoxia and hypoxia-inducible factor-1alpha promote growth factor-induced proliferation of human vascular smooth muscle cells. Am J Physiol 2006;290:H2528-34
   Web of Science ®Google Scholar
• Cohen MH, Johnson JR, Pazdur R. US Food and Drug Administration drug approval summary: conversion of imatinib mesylate (sti571; gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 2005;11:12-19
   PubMed Web of Science ®Google Scholar
• Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006;312:1175-8
   PubMed Web of Science ®Google Scholar
• Gschwind HP, Pfaar U, Waldmeier F, Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005;33:1503-12
   PubMed Web of Science ®Google Scholar
• Le Coutre P, Kreuzer KA, Pursche S, Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 2004;53:313-23
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H, Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879-94
   PubMed Web of Science ®Google Scholar
• Nakamura K, Akagi S, Ogawa A, Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 2011. [Epub ahead of print]
   Web of Science ®Google Scholar
• Vantler M, Caglayan E, Zimmermann WH, Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells. Only phosphatidylinositol 3′-kinase is important. J Biol Chem 2005;280:14168-76
   PubMed Web of Science ®Google Scholar
• Vantler M, Karikkineth BC, Naito H, PDGF-BB protects cardiomyocytes from apoptosis and improves contractile function of engineered heart tissue. J Mol Cell Cardiol 2010;48:1316-23
   PubMed Web of Science ®Google Scholar
• Sato N, Narita M, Takahashi M, The effects of STI571 on antigen presentation in dendritic cells generated from patients with chronic myelogenous leukemia. Hematol Oncol 2003;2:67-75
   Google Scholar
• Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-13
   PubMed Web of Science ®Google Scholar
• Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006;145:152-3
   PubMed Web of Science ®Google Scholar
• Souza R, Sitbon O, Parent G, Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006;61:736
   PubMed Web of Science ®Google Scholar
• ten Freyhaus H, Dumitrescu D, Bovenschulte H, Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 2009;98:265-7
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Morrell NW, Hoeper MM, Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010;182:1171-7
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Morrell NW, Hoeper MM, Long term use of imatinib in patients with severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;181(Suppl):abstract 2513
   Google Scholar
• Hoeper M, Barst RJ, Galie N, Imatinib in pulmonary arterial hypertension, a randomized efficacy study (IMPRES). Eur Respir J 2011;38(Suppl):abstract 413
   Google Scholar
• Press release, Novartis, September 26, 2011
   Google Scholar
• Druker BJ, Guilhot F, O´Brian SG, IRIS investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
   PubMed Web of Science ®Google Scholar
• Tong WG, Kantarjian H, O'Brien S, Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer 2010;116:3152-9
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16
   PubMed Web of Science ®Google Scholar
• Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010;106:21-34
   PubMed Web of Science ®Google Scholar
• Fernandez A, Sanguino A, Peng Z, An anticancer c-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 2007;117:4044-54
   PubMed Web of Science ®Google Scholar
• Atallah E, Durand JB, Kantarijan H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007;110:1233-7
   PubMed Web of Science ®Google Scholar
• Dumitrescu D, Seck C, Ten Freyhaus H, Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukemia. Eur Respir J 2011;38:218-20
   PubMed Web of Science ®Google Scholar
• Hennigs JK, Keller G, Baumann HJ, Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 2011;11:30
   PubMedGoogle Scholar
• Mattei D, Feola M, Orzan F, Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009;43:967-8
   PubMed Web of Science ®Google Scholar
• Quinta's-Cardama A, Kantarijan H, O'Brien S, Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-14
   PubMed Web of Science ®Google Scholar
• Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009;33:861-4
   PubMed Web of Science ®Google Scholar
• Abe K, Toba M, Alzoubi A, Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am J Respir Crit Care Med 2011. [Epub ahead of print]
   Web of Science ®Google Scholar
• Young KC, Torres E, Hehre D, Neonatal c-kit mutant mice exhibit decreased susceptibility to hypoxia-induced pulmonary hypertension. Circulation 2009;120:S750-1
   Web of Science ®Google Scholar
• Gambaryan N, Perros F, Montani D, Imatinib inhibits bone marrow-derived c-kit+ cell mobilization in hypoxic pulmonary hypertension. Eur Respir J 2010;35:1209-11
   PubMedGoogle Scholar
• Dahal BK, Kosanovic D, Kaulen C, Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir Res 2011;12:60
   PubMed Web of Science ®Google Scholar
• Sitbon O, Galie N. Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals. Eur Respir Rev 2010;19:272-8
   PubMedGoogle Scholar
• Delgado JF, Conde E, Sanchez V, Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005;7:1011-16
   PubMed Web of Science ®Google Scholar
• Ogawa A, Firth AL, Yao W, Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2009;297:L666-76
   PubMed Web of Science ®Google Scholar
• Baroni SS, Santillo M, Bevilacqua F, Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76
   PubMed Web of Science ®Google Scholar
• Dahal BK, Cornitescu T, Tretyn A, Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med 2010;181:158-67
   PubMed Web of Science ®Google Scholar
• Izikki M, Guignabert C, Fadel E, Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 2009;119:512-23
   PubMed Web of Science ®Google Scholar
• Merklinger SL, Jones PL, Martinez EC, Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 2005;112:423-31
   PubMed Web of Science ®Google Scholar
• Berghausen E, Janssen W, Vantler M, The PI 3-kinase isoform p110alpha is essential for growth factor-induced vascular remodeling in pulmonary hypertension. Eur Heart J 2011;32(Suppl):abstract 3072
   Google Scholar